Literature DB >> 8595265

Immunohistological analyses of neutral glycosphingolipids and gangliosides in normal mouse skeletal muscle and in mice with neuromuscular diseases.

M Cacic1, K Sostarić, S Weber-Schürholz, J Müthing.   

Abstract

The expression of neutral glycosphingolipids (GSLs) and gangliosides was investigated in cryosections of normal mouse skeletal muscle and in muscle of mice with neuromuscular diseases using indirect immunofluorescence microscopy. Transversal and longitudinal sections were immunostained with specific polyclonal antibodies against lactosylceramide, lacto-N-neotetraosylceramide, globoside, GM3(Neu5Ac), GM3(Neu5Gc) and Gm1(Neu5Ac) as well as monoclonal anti-Forssman GSL antibody. In normal CBA/J mouse muscle (control) the main immunohistochemically detected ganglioside was GM3(Neu5Ac) followed by moderately expressed GM3(Neu5Gc) and GM1. The neutral GSLs lactosylceramide and globoside were stained with almost identical, high fluorescence intensity. Low amounts of lacto-N-neotetraosylceramide and trace quantities of Forssman GSL were immunostained. All GSLs were detected in the sarcolemma, but also in considerable amounts at the intracellular level. Mice with neuromuscular diseases were the A2G-adr mouse mutant (a model for human recessive myotonia of Becker type), the BL6-wr mutant (a model for motor neuron disease) and the BL10-mdx mouse mutant (a model for human Duchenne muscular dystrophy). No changes in GSL expression were found in the A2G-adr mouse, while muscle of the BL6-wr mouse showed increased intensity of immunofluorescence in stainings with anti-lactosylceramide and anti-GM3(Neu5Ac) antibodies. Muscle of BL10-mdx mice showed the most prominent changes in GSL expression with reduced fluorescence intensity for all antibodies. Major differences were not observed in the intensities of GSLs, but there were significant differences in the patterns of distribution on plasma membrane and at the subcellular level. The exact nature and pathogenesis of these changes should be elucidated since such investigations could furnish advances in understanding the functional role of neutral GSLs and gangliosides in normal as well as in diseased muscle.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8595265     DOI: 10.1007/bf00731270

Source DB:  PubMed          Journal:  Glycoconj J        ISSN: 0282-0080            Impact factor:   2.916


  49 in total

1.  The skeletal muscle chloride channel in dominant and recessive human myotonia.

Authors:  M C Koch; K Steinmeyer; C Lorenz; K Ricker; F Wolf; M Otto; B Zoll; F Lehmann-Horn; K H Grzeschik; T J Jentsch
Journal:  Science       Date:  1992-08-07       Impact factor: 47.728

2.  Denervation-induced changes in lectin binding to sarcolemmal glycoproteins: exposure of cryptic recognition sites.

Authors:  R C Iannello; P L Jeffrey
Journal:  Glycobiology       Date:  1992-06       Impact factor: 4.313

3.  External labeling of cell surface galactose and galactosamine in glycolipid and glycoprotein of human erythrocytes.

Authors:  C G Gahmberg; S I Hakomori
Journal:  J Biol Chem       Date:  1973-06-25       Impact factor: 5.157

4.  Ganglioside treatment of neuropathy in diabetic mice.

Authors:  F Norido; R Canella; A Gorio
Journal:  Muscle Nerve       Date:  1982-02       Impact factor: 3.217

5.  Dystrophin: the protein product of the Duchenne muscular dystrophy locus.

Authors:  E P Hoffman; R H Brown; L M Kunkel
Journal:  Cell       Date:  1987-12-24       Impact factor: 41.582

6.  The fine structure of the cervical spinal cord, ventral root and brachial nerves in the wobbler (wr) mouse.

Authors:  J M Andrews
Journal:  J Neuropathol Exp Neurol       Date:  1975-01       Impact factor: 3.685

7.  Trial of ganglioside therapy for diabetic neuropathy.

Authors:  M Hallett; T Flood; N Slater; J Dambrosia
Journal:  Muscle Nerve       Date:  1987 Nov-Dec       Impact factor: 3.217

8.  Expression of neutral glycosphingolipids and gangliosides in human skeletal and heart muscle determined by indirect immunofluorescence staining.

Authors:  M Cacić; J Müthing; I Kracun; U Neumann; S Weber-Schürholz
Journal:  Glycoconj J       Date:  1994-10       Impact factor: 2.916

9.  Electromyographic study of diabetic and alcoholic polyneuropathic patients treated with gangliosides.

Authors:  S Bassi; M G Albizzati; E Calloni; L Frattola
Journal:  Muscle Nerve       Date:  1982 May-Jun       Impact factor: 3.217

10.  Selective detection of terminally alpha 2-3 and alpha 2-6 sialylated neolacto-series gangliosides by immunostaining on thin layer chromatograms.

Authors:  J Müthing; U Neumann
Journal:  Biomed Chromatogr       Date:  1993 May-Jun       Impact factor: 1.902

View more
  5 in total

Review 1.  Lipid glycosylation: a primer for histochemists and cell biologists.

Authors:  Jürgen Kopitz
Journal:  Histochem Cell Biol       Date:  2016-12-20       Impact factor: 4.304

2.  Glycosphingolipid expression in human skeletal and heart muscle assessed by immunostaining thin-layer chromatography.

Authors:  J Müthing; M Cacić
Journal:  Glycoconj J       Date:  1997-01       Impact factor: 2.916

3.  Ganglioside GM3 levels are altered in a mouse model of HIBM: GM3 as a cellular marker of the disease.

Authors:  Thomas Paccalet; Zoé Coulombe; Jacques P Tremblay
Journal:  PLoS One       Date:  2010-04-07       Impact factor: 3.240

Review 4.  Sphingolipids in Obesity and Correlated Co-Morbidities: The Contribution of Gender, Age and Environment.

Authors:  Enrica Torretta; Pietro Barbacini; Nasser M Al-Daghri; Cecilia Gelfi
Journal:  Int J Mol Sci       Date:  2019-11-24       Impact factor: 5.923

5.  Implications for the mammalian sialidases in the physiopathology of skeletal muscle.

Authors:  Alessandro Fanzani; Alessandra Zanola; Fiorella Faggi; Nadia Papini; Bruno Venerando; Guido Tettamanti; Maurilio Sampaolesi; Eugenio Monti
Journal:  Skelet Muscle       Date:  2012-11-01       Impact factor: 4.912

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.